217 Parks Hall
500 West 12th Ave.
Columbus, OH 43210
Phone: (614) 292-2266
Fax: (614) 292-2588
Within the broad scope of the pharmaceutical sciences there are many research possibilities. Below is a Topical Index of research specialties and investigators in the College of Pharmacy.
Jessie Lai-Sim Au: pharmacodynamics of anticancer and anti-AIDS drugs in cultured cells, tissues, animals and patients; with an emphasis on treatment of bladder, head and neck, prostate, breast, and ovarian cancer.
Robert Brueggemeier: the role of steroids in the growth of breast cancer and in the development of drugs that interfere with hormone action / aromatase inhibitors.
Kenneth K. Chan applications of stable isotopes in pharmacokinetics, metabolism and mechanism of action; alkylating agents / cancer chemotherapy and drug development / liposome drug formulation / analytical method development / mass spectrometry.
Ching-Shih Chen: mechanism-based design of novel therapeutic agents that selectively target apoptosis machinery in cancer cells at cellular or epigenetic levels.
Robert W. Curley, Jr.: the use of vitamin A and its retinoid analogues as anticancer agents / stereoselective syntheses of stable isotope-labeled amino acids and NMR studies of drug receptor interactions.
James T. Dalton: ligand binding domains of androgen, glucocorticoid, progesterone, and estrogen receptors.
George Hinkle: nuclear pharmacy with emphasis on the medical use of radionuclides and radiolabeled antibodies.
Chenglong Li: Structure-based and computer-aided drug design and discovery (SBDD/CADD), molecular docking, molecular dynamics, computational chemistry, X-ray protein crystallography, Anti-cancer, anti-diabetic and anti-infectious molecular design and simulation.
Pui-Kai (Tom) Li: drug development (steroid sulfatase inhibitors) for the treatment of breast cancer / designing melatonin analogs to elucidate the physiological roles of melatonin in humans.
Thomas D. Schmittgen: development of new cancer therapies or diagnostics, gene expression, targeted drug delivery for cancer therapy. Areas of study include: 1) development of RNA aptamers as targeting agents for prostate and breast cancer; 2) quantitative PCR as a tool to study gene expression in cancerous and noncancerous tissues; 3) role of small, noncoding (i.e. micro RNAs) in cancer development.
Werner Tjarks: Nucleosides, folates, and mitochondria targeting agents for cancer- and antiviral therapy
M. Guillaume Wientjes: pharmacokinetics and pharmacodynamics of drugs for bladder and prostate cancer in patients, animals, and cell culture / use of regional and targeted drug delivery.
John A. Bauer: the roles and mechanisms of nitric oxide control in disease, especailly cardiovascular disease / cardiovascular complications assoicated with congestive heart failure, diabetes, and AIDS / nitric oxide control in urological complications of diabetes.
Cynthia A. Carnes: cardiovascular pharmacology / electrophysiological effects of drugs that act on the heart.
James D. Coyle: drug therapy in patients with kidney disease, including those on dialysis. His goal is to help patients and their healthcare providers achieve targeted therapeutic outcomes using a comprehensive pharmacotherapeutic approach, including application of clinical pharmacokinetic and dynamic principles. Treatment of hypertension in renal failure patients is of particular interest.
Robert J. Lee: receptor-mediated targeted drug delivery systems.
Sylvan G. Frank: design and evaluation of drug delivery systems, with an emphasis on emulsions, liposomes, and liquid crystals / micelle stability and solubilization, small-particle formation and microencapsulation, iontophoresis, percolation theory, and fractal geometry.
William L. Hayton: minimizing environment toxicity through understanding pharmacokinetics and metabolism of aquatic species.
Daren L. Knoell studies the lung microenvironment with a particular emphasis on host response during inflammatory stress. Investigations incorporate human lung epithelial cell culture, animal and human studies and aspects of immunology as well as cellular and molecular biology. The most current studies aim to improve our understanding of emphysema and fibrosis pathogenesis.
[ back to top ]
Craig Pedersen: medication use system epidemiology and improvement, patient safety technologies, hospital pharmacy, pharmacy workforce, and leadership.
[ back to top ]
Esperanza J. Carcache de Blanco dietary supplements, traditional medicine, natural products drug discovery.
A. Douglas Kinghorn: research interests include the discovery of natural product lead compounds from tropical rainforest plants, particularly those with potential anticancer, cancer chemopreventive, and oral antimicrobial activity. He is also interested in the scientific evaluation of botanical dietary supplements and the development of potently sweet substances of natural origin.
Larry W. Robertson: fermentation and microbial products, microbiological transformations of drugs, antibiotics, drug metabolism, metabolism and biological activities of cannabinoids.
[ back to top ]
James M. McAuley specializes in drugs used to treat epilepsy. He is also interested in pharmacokinetics and phamacodynamics of centrally acting rugs and influence of gender and hormones on drug response.
Dennis B. McKay: the role of nicotinic acetycholine nicotinic receptor in regulating adrenal catecholamine secretion / cellular and molecular pharmacology of neurosecretory mechanisms.
Popat N. Patil: autonomic nervous system pharmacology with emphasis on steric aspects of drug receptor interactions, desensitization, morphology of sensory and synaptic receptors / ocular pharmacology, and drug melanin interactions.
Lane J. Wallace: mechanisms by which abused drugs change the brain and its response to drugs / neurodegenerative diseases / bladder dysfunction in diabetes.
Anthony P. Young: molecular and cellular pharmacology / regulation of glutamine synthetase gene expression during retinal development, glucocorticoid-mediated muscle atrophy, and nitric oxide synthase gene expression.
Jessie Lai-Sim Au: pharmacodynamics of anticancer and anti-AIDS drugs in cultured cells, tissues, animals and patients; with an emphasis on treatment of bladder, head and neck, prostate, breast, and ovarian cancer.
John A. Bauer: the roles and mechanisms of nitric oxide control in disease, especailly cardiovascular disease / cardiovascular complications assoicated with congestive heart failure, diabetes, and AIDS / nitric oxide control in urological complications of diabetes.
James T. Dalton: ligand binding domains of androgen, glucocorticoid, progesterone, and estrogen receptors.
Rajesh Balkrishnan: Dr. Balkrishnan is a quantitative health services researcher, and his research generally focuses on application of statistical methodology in examining issues related to effectiveness of medical care delivery and pharmaceutical outcomes in chronic disease. He has led and participated in several research projects in the area of health outcomes evaluation and pharmaceutical health services research.
Enrique C. Seoane: pharmaceutical policy and economics in the Americas, Medicare and Medicaid drug benefits, drug financing in developing countries, the role of generic drugs in the health care system, and access of population to pharmaceuticals.
Sheryl L. Szeinbach: distribution of pharmaceutical products and services / service delivery decision-making processes that involve utility analysis (pharmacoeconomics) and risk assessment / organizational structure, automation, and information technology.
[back to top ]
Robert
Brueggemeier: the role of steroids in the
growth of breast cancer / development of drugs that interfere
with hormone action, with a major focus on aromatase
inhibitors.
Ching-Shih Chen: mechanism-based design of novel therapeutic agents
that selectively target apoptosis machinery in cancer cells at cellular or
epigenetic levels
Robert W. Curley, Jr.: use of vitamin A and its retinoid analogues as anticancer agents / stereoselective syntheses of stable isotope-labeled amino acids / NMR studies of drug receptor interactions.
Chenglong Li: Structure-based and computer-aided drug design and discovery (SBDD/CADD), molecular docking, molecular dynamics, computational chemistry, X-ray protein crystallography, Anti-cancer, anti-diabetic and anti-infectious molecular design and simulation.
Pui-Kai (Tom) Li: drug development (steroid sulfatase inhibitors) for the treatment of breastcancer / designing melatonin analogs to elucidate the physiological roles of melatonin in humans.
Larry W. Robertson: fermentation and microbial products, microbiological transformations of drugs, antibiotics, drug metabolism, metabolism and biological activities of cannabinoids.
Werner Tjarks: Nucleosides, folates, and mitochondria targeting agents for cancer- and antiviral therapy
Karl Werbovetz: discovery and development of drugs to treat disease caused by parasitic organisms.
A. Douglas Kinghorn: research interests include the discovery of natural product lead compounds from tropical rainforest plants, particularly those with potential anticancer, cancer chemopreventive, and oral antimicrobial activity. He is also interested in the scientific evaluation of botanical dietary supplements and the development of potently sweet substances of natural origin.
[ back to top ]
Craig Pedersen: medication use system epidemiology and improvement, patient safety technologies, hospital pharmacy, pharmacy workforce, and leadership.
Sheryl L. Szeinbach: distribution of pharmaceutical products and services / service delivery decision-making processes that involve utility analysis (pharmacoeconomics) and risk assessment / organizational structure, automation, and information technology.
[ back to top ]
Jessie Lai-Sim Au: pharmacodynamics of anticancer and anti-AIDS drugs in cultured cells, tissues, animals and patients; with an emphasis on treatment of bladder, head and neck, prostate, breast, and ovarian cancer.
Kenneth K. Chan: applications of stable isotopes in pharmacokinetics, metabolism and mechanism of action; alkylating agents; cancer chemotherapy and drug development; liposome drug formulation; analytical method development; mass spectrometry.
James T. Dalton: ligand binding domains of androgen, glucocorticoid, progesterone, and estrogen receptors.
Sylvan G. Frank: design and evaluation of drug delivery systems, with an emphasis on emulsions, liposomes, and liquid crystals / micelle stability and solubilization, small-particle formation and microencapsulation, iontophoresis, percolation theory, and fractal geometry.
William L. Hayton directs research that has the goal of minimizing environment toxicity through understanding pharmacokinetics and metabolism of aquatic species.
Thomas D. Schmittgen: development of new cancer therapies or diagnostics, gene expression, targeted drug delivery for cancer therapy. Areas of study include: 1) development of RNA aptamers as targeting agents for prostate and breast cancer; 2) quantitative PCR as a tool to study gene expression in cancerous and noncancerous tissues; 3) role of small, noncoding (i.e. micro RNAs) in cancer development.
M. Guillaume Wientjes: pharmacokinetics and pharmacodynamics of drugs for bladder and prostate cancer in patients, animals, and cell culture / use of regional and targeted drug delivery.
John A. Bauer: the roles and mechanisms of nitric oxide control in disease, especailly cardiovascular disease / cardiovascular complications assoicated with congestive heart failure, diabetes, and AIDS / nitric oxide control in urological complications of diabetes.
Dale G. Hoyt: regulation of DNA damage and programmed cell death (apoptosis) by matrix and soluble factors in the extracellular environment / signal transduction processes that lead to adverse effects of drugs.
Kari Hoyt: the molecular mechanisms underlying the loss of neurons in neurodegenerative diseases.
Keli Hu: The long-term research interest in Dr. Hu's laboratory is to study the function and regulation of metabolically-sensitive ion channels using cellular and molecular approaches, with a special emphasis on traffic regulation, molecular mechanisms and their physiological relevance, particularly as these processes relate to human diseases.
Lakhu Keshvara: Cellular and Molecular Basis of Neuronal Development. Defects in development are known to contribute to the pathogenesis of various neurological disorders in the adult. The goal of my lab is to understand the cellular and molecular basis of brain development. Development of the mammalian brain involves a complex series of neuronal migration and positioning events. Recent studies involving spontaneous and targeted mouse mutants have led to the identification of a signaling pathway that governs normal development. This pathway, known as the Reelin signaling pathway, involves a large glycoprotein known as Reelin. Binding of Reelin to lipoprotein receptors VLDLR and ApoER2 on the surface of migrating neurons, triggers a signaling cascade within these neurons. Our knowledge of these downstream molecular events is limited, but Reelin-induced intracellular signaling is critical to normal development. Therefore, there is a potential for numerous well-defined projects aimed at investigating various aspects of Reelin signaling. The laboratory uses a multidisciplinary approach that involves techniques in molecular biology, cell biology, biochemistry, neuroanatomy, and biophysics.
Dennis B. McKay: the role of nicotinic acetycholine nicotinic receptor in regulating adrenal catecholamine secretion / cellular and molecular pharmacology of neurosecretory mechanisms.
Popat N. Patil: autonomic nervous system pharmacology with emphasis on steric aspects of drug receptor interactions, desensitization, morphology of sensory and synaptic receptors / ocular pharmacology, and drug melanin interactions.
Lane J. Wallace mechanisms by which abused drugs change the brain and its response to drugs / neurodegenerative diseases / bladder dysfunction in diabetes.
Anthony P. Young: molecular and cellular pharmacology / regulation of glutamine synthetase gene expression during retinal development, glucocorticoid-mediated muscle atrophy, and nitric oxide synthase gene expression.
Stuart J. Beatty: pharmacist reimbursement, primary/ambulatory Care, pain management, educational technology.
Cari C. Brackett: interests include infectious disease, AIDS, and optimizing resuscitation.
Robert A. Buerki: professional ethics and pharmacy practice, the history of pharmacy, and pharmacy communications.
James D. Coyle: drug therapy in patients with kidney disease, including those on dialysis. His goal is to help patients and their healthcare providers achieve targeted therapeutic outcomes using a comprehensive pharmacotherapeutic approach, including application of clinical pharmacokinetic and dynamic principles. Treatment of hypertension in renal failure patients is of particular interest.
Joseph F. Dasta: critical care pharmacy, critical care health outcomes and pharmacokinetics.
George Hinkle: nuclear pharmacy with emphasis on the medical use of radionuclides and radiolabeled antibodies.
Daren L. Knoell: studies the lung microenvironment with a particular emphasis on host response during inflammatory stress. Investigations incorporate human lung epithelial cell culture, animal and human studies and aspects of immunology as well as cellular and molecular biology. The most current studies aim to improve our understanding of emphysema and fibrosis pathogenesis.
James M. McAuley: We are working on many new and exciting projects in our expansive laboratory, also known as the outpatient epilepsy clinic. My research focus is the patient with epilepsy. We have a particular focus on women's issues in epilepsy. We have projects looking at the influence of hormones on seizure activity, how pregnancy influences epilepsy and its' treatments, and many more. We have a new clinic with the High Risk OB practitioners providing collaborative pharmaceutical care for pregnant women with epilepsy. There is an intriguing relationship between folate and antiepileptic drugs that has become a recent focus of efforts. Another new project is looking at how we can convert a "pharmacoresistant" patient to someone more sensitive to therapy. Other projects include assessing knowledge about epilepsy by patients and healthcare professionals. The interested student(s) may take on a portion of one of these as their project or develop their own. The many fascinating aspects of clinical research will be discovered.
Milap C. Nahata: pediatric and antimicrobial pharmacokinetics and therapy.
Maria Pruchnicki: areas of interest include ambulatory care and chronic disease management, pharmacokinetics, and pharmacy education, including educational technology and distance learning.
James A. Visconti: drug information / infectious disease therapeutics.
Chenglong Li: Structure-based and computer-aided drug design and discovery (SBDD/CADD), molecular docking, molecular dynamics, computational chemistry, X-ray protein crystallography, Anti-cancer, anti-diabetic and anti-infectious molecular design and simulation.
